containing the glycoprotein component of the human thyrotropin receptor. Antibodies 129H8 and 122G3 appear to be representative of inhibiting or "blocking" antibodies in Graves disease sera. Thus they have no intrinsic stimulatory action in assays of thyroid function but rather inhibit thyrotropin activity in the assays tested. These two antibodies do not react with human thyroid gangliosides but are strong inhibitors of thyrotropin binding to liposomes containing the high-affinity glycoprotein component from human, bovine, and rat thyroid membranes. The data unequivocally establish the pluritopic nature of the immunoglobulins in Graves disease and relate individual components or determinants of the thyrotropin receptor structure with specific autoimmune immunoglobulins.
Multiple experiments have suggested that immunoglobulins in the sera of patients with Graves disease serve as the effector of thyroid overactivity and that this action is mediated by the thyrotropin (TSH) receptor (1) (2) (3) . The variable correlation between the ability ofimmunoglobulin preparations from Graves disease patients (GD Ig) to inhibit TSH binding or adenylate cyclase activity and to act as intrinsic stimulating antibodies (1) (2) (3) and the presence of growth activators and depressors in GD Ig. (4) suggest that a spectrum of antibodies might exist with distinct antigenic determinants.
To clarify specific effector roles of individual immunoglobulins and their relation to TSH receptor structure, monoclonal antibodies have been obtained by fusing mouse myeloma cells with peripheral lymphocytes from patients with active Graves disease. These antibodies represent clonal idiotypes ofnaturally determined immunoglobulins in patients. with Graves disease.
In the present report we detail the properties of four such heterohybridoma antibodies and compare these properties with those of monoclonal antibodies derived from experiments with solubilized bovine and human TSH receptor immunizations and fusions (5) (6) (7) .
MATERIALS AND METHODS
Patients. Six patients with active Graves disease served as lymphocyte donors. The diagnosis of Graves disease was based on clinical thyrotoxicosis with diffuse toxic goiter, exophthalmos, increased blood levels of thyroid hormone, and increased 1I uptake.
Production of Lymphocyte Hybridoma Clones. Peripheral lymphocytes were harvested by Ficoll-Hypaque gradient centrifugation of blood within 30 min of venipuncture. Lymphocytes were washed twice with Hanks balanced salt solution, and cell number was adjusted to 1 x 107/ml in Dulbecco modified Eagle medium. Polyethylene glycol fusion with 5 X 107 P3-NS1/ 1-AG4-1 mouse myeloma cells was performed as described (5, 6, 8) . The fusion products were dispersed in "super" hypoxanthine/aminopterin/thymidine selection medium (5, 6, 8) ; additional medium was added every 4 days until visible hybridoma colonies had reached the 100-to 200-cell stage. The successful fusion rate consistently approximated 1.5% per plate.
Screening. A two-stage screening procedure using bovine thyroid membranes was utilized as detailed (5) (6) (7) . In the first stage, hybridomas producing antibody reactive with thyroid membranes were identified by using 125I-labeled staphylococcal protein A or a "asI-labeled goat anti-human IgG F(ab')2 fragment-specific antibody. In the second stage, the assay was repeated with competing 1 AM TSH added during the initial incubation of membranes and hybridoma medium. Hybridoma antibodies reactive with thyroid membranes in the first screening assay but blocked by unlabeled TSH in the second were chosen as potential TSH receptor antibodies.
Expansion of Antibody-Producing Hybridomas and Antibody Purification. Hybridomas were subcloned for 2 months to stabilize cell morphology and antibody production. Medium from overgrown cultures was harvested by centrifugation at 500 x g for 10 min; IgG preparations ofmonoclonal antibodies were prepared by protein A-Sepharose column chromatography (7) or ammonium sulfate precipitation (5, 6) (Table  1) . Antibodies 208F7 and 206H3 were also able to increase cAMP levels in the human thyroid cell cultures. Dose-dependent stimulatory activity by these two antibodies was also evident with FRTL thyroid cells (Fig. 2A) ; furthermore, their inhibition (antagonism) of the TSH response could be shown to be competitive at high (10 nM) TSH concentrations (Fig. 2C) and to be associated with more than additive agonism at low (0.1 nM) TSH concentrations (Fig. 2B) . Some GD Ig have also been shown to elicit more than additive stimulation (agonism) of adenylate cyclase activity when incubated with cholera toxin (21) ; the 206H3 antibody had this characteristic (Table 1) . Both the 208F7 and 206H3 antibodies were active in the mouse bioassay, as was the 22A6 "stimulating" antibody to the bovine TSH receptor previously described (7) (Fig. 3A) . The antibody activity pattern in the mouse bioassay resembled that of TSH rather than the time course ofa long-acting thyroid-stimulating immunoglobulin (Fig. 3B) . In sum, antibodies 208F7 and 206H3 demonstrated the stimulatory properties defined for autoimmune stimulators present in the sera of patients with Graves disease; they also exhibit agonism-competitive antagonism phenomena with respect to TSH which additionally characterize them as antibodies against a determinant associated with the TSH receptor structure.
Inhibition of TSH-induced cAMP levels in human cell cultures by antibodies 129H8 or 122G3 was also associated with their ability to inhibit TSH-induced cAMP levels competitively in the FRTL culture system (data not shown, but similar to nor were they able to increase cAMP levels in the FRTL system when tested alone ( Fig. 2A) . Antibody (0.2 mg/ml) and TSH (1 milliunit/ml) were mixed and injected together; assays were at 2 hr. (23) , whereas the blocking antibodies [129H8, 122G3, 11E8, 13D11, 59C9, and 60F5 (5, 6)] appear to be primarily reactive with the high-affinity glycoprotein receptor component (23) . Within this preliminary generalization, however, several additional comments should be made.
First, the species specificity exhibited by the stimulating antibodies with respect to interactions with gangliosides may provide a physicochemical basis for the "species specificity" exhibited by some autoimmune stimulating antibodies in Graves disease sera (1) (2) (3) 21) . Preliminary results show that antibodies 206H3 and 208F7 do exhibit species specificity with respect to their ability to stimulate human and rat FRTL cells in comparison to bovine thyroid membranes.
Second, the simple generalization does not preclude the existence of a wide panel of antibodies with individual bioactivity and membrane component reactivity patterns. Several possibilities could account for this. For example, the carbohydrate determinant of the ganglioside could also exist on the glycoprotein receptor component, clones could recognize a conglomerate structure composed of both receptor components which might exist in situ, or monoclonal antibodies could view the TSH receptor complex in situ from multiple three-dimensional orientations. Any of these possibilities could account for the 208F7 and 122G3 discrepancy noted above.
Third, it has been predicted that autoimmune antibodies in Graves disease sera can affect thyroid cell growth, possibly by using mechanisms analogous to those for insulin or somatomedins, rather than operate via the cAMP message system (4). The present report confirms this by showing that at least one antibody, 129H8, can increase growth without being a stimulator in other assays but establishes that antibodies perturbing growth are nevertheless related to the TSH receptor structure.
